Benzinga | Nov 5, 2020 05:39PM EST

CytomX Therapeutics Q3 EPS $(0.32) Beats $(0.48) Estimate, Sales $17.80M Beat $16.34M Estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.48) by 33.33 percent. This is a 38.46 percent increase over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $17.80 million which beat the analyst consensus estimate of $16.34 million by 8.94 percent. This is a 66.17 percent increase over sales of $10.71 million the same period last year.